Phase 2 N=18 Randomized Treatment

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

Epistaxis · Hereditary Hemorrhagic Telangiectasia

Bottom Line

View on ClinicalTrials.gov: NCT01408732 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2018

Primary outcome: Primary: Severityof Epistaxis — -0.4578; -1.4375 units on a scale

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Sclerotherapy (Drug); Standard Treatment (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Minnesota
Primary completion: Sep 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Severityof Epistaxis	-0.4578; -1.4375	—

Summary

The purpose of this study is to test a novel and tolerable office-based treatment method, sclerotherapy with sodium tetradecyl sulfate, for recurrent epistaxis (nosebleeds) related to Hereditary Hemorrhagic Telangiectasia (HHT) disease.

Eligibility Criteria

Inclusion Criteria

a clinical diagnosis of HHT based on the Curacoa Criteria
age 18 and older
cognitive ability and willingness to sign the study consent form and complete the study forms and questionnaires

Exclusion Criteria

previous sclerotherapy with Sodium Tetradecyl Sulfate

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01408732). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.